Cyclosporin A

sc-3503

Material Safety Data Sheet

Section 1 - CHEMICAL PRODUCT AND COMPANY IDENTIFICATION

PRODUCT NAME
Cyclosporin A

STATEMENT OF HAZARDOUS NATURE

NFPA

SUPPLIER
Company: Santa Cruz Biotechnology, Inc.
Address:
2145 Delaware Ave
Santa Cruz, CA 95060
Telephone: 800.457.3801 or 831.457.3800
Emergency Tel: CHEMWATCH: From within the US and Canada: 877-715-9305
Emergency Tel: From outside the US and Canada: +800 2436 2255 (1-800-CHEMCALL) or call +613 9573 3112

PRODUCT USE
Immunosuppressant with little effect on bone marrow. Used to prolong the survival of organ and tissue transplants. Given by mouth or intramuscularly. Studies in animals indicate that cyclosporin inhibits the development of cell-mediated reactions, including allograft immunity, delayed cutaneous hypersensitivity, experimental allergic encephalomyelitis, Freund's adjuvant arthritis, graft-versus-host disease and also T-cell dependent antibody production. Also inhibits lymphokine production and release and appears to block resting lymphocytes in the G0 or G1 phase of the cell cycle. A metabolite of the fungi Trichoderma polysporum. Cyclic polypeptide consisting of 9 amino-acids. Inhibits the T-cell receptor signal transduction pathway via the formation of cyclosporin A-cyclophilin complex that inhibits calcineurin (protein phosphatase 2B). Calcineurin inhibition interferes with other physiological processes as well. Inhibits nitric oxide synthesis induced by interleukin 1alpha, lipopolysaccharides and TNFalpha.

SYNONYMS

Section 2 - HAZARDS IDENTIFICATION

CANADIAN WHMIS SYMBOLS

EMERGENCY OVERVIEW
RISK
Harmful if swallowed.
May impair fertility.

POTENTIAL HEALTH EFFECTS
ACUTE HEALTH EFFECTS

SWALLOWED
- Accidental ingestion of the material may be harmful; animal experiments indicate that ingestion of less than 150 gram may be fatal or may produce serious damage to the health of the individual.
- At sufficiently high doses the material may be nephrotoxic (i.e., poisonous to the kidney).
- Macrolides comprise a large group of antibiotics derived from Streptomyces spp. having in common a macrocyclic lactone ring to which one or more sugars are attached. They are all weak bases. The most common side effect produced by the family of macrolide antibiotics is gastrointestinal discomfort. Supra-infections may occur although these are rare. Several macrolides produced allergic sensitization but, again, these are rare. Symptoms include watery eyes, shortness of breath, nasal congestion, choking, coughing and wheezing. Allergic skin reactions have also occurred. Exposure to at least one member of the family, erythromycin, at high concentrations, has produced reversible deafness (ototoxicity). Systemic reactions including fever, rash, and lymph-node pain or swelling have been produced by the avermectin group. Ivermectin has produced ataxia (incoordination), lethargy, bradypnea (slowed breathing), vomiting, mydriasis (dilated pupils), sedation, tremors and death in animals. The avermectin group (anthelmintics, insecticides and acaricides) mediate the transmission of gamma-butyric acid (GABA), an inhibitory neurotransmitter, in mammals thus causing paralysis. Hepatotoxic effects with transient disturbances and jaundice have resulted from the use of oleandomycin. Transient alterations in heart rate/ rhythm have also been produced by several members of the family (notably tilmicosin). Heart muscle degeneration, characterized by small areas of cell death have also been reported in animals exposed to tilmicosin. Cross-resistance is often observed between the macrolide, lincosamide and streptogramin group of antibiotics.

EYE
- Although the material is not thought to be an irritant, direct contact with the eye may cause transient discomfort characterized by tearing or conjunctival redness (as with windburn). Slight abrasive damage may also result. The material may produce foreign body irritation in certain individuals.

SKIN
- Skin contact is not thought to produce harmful health effects (as classified using animal models). Systemic harm, however, has been identified following exposure of animals by at least one other route and the material may still produce health damage following entry through wounds, lesions or abrasions. Good hygiene practice requires that exposure be kept to a minimum and that suitable gloves be used in an occupational setting.
- Open cuts, abraded or irritated skin should not be exposed to this material.
- Entry into the blood-stream, through, for example, cuts, abrasions or lesions, may produce systemic injury with harmful effects. Examine the skin prior to the use of the material and ensure that any external damage is suitably protected.

INHALED
- The material is not thought to produce either adverse health effects or irritation of the respiratory tract following inhalation (as classified using animal models). Nevertheless, adverse effects have been produced following exposure of animals by at least one other route and good hygiene practice requires that exposure be kept to a minimum and that suitable control measures be used in an occupational setting.
- Persons with impaired respiratory function, airway diseases and conditions such as emphysema or chronic bronchitis, may incur further disability if excessive concentrations of particulate are inhaled.

CHRONIC HEALTH EFFECTS
- There is ample evidence that this material can be regarded as being able to cause cancer in humans based on experiments and other information. Ample evidence exists from experimentation that reduced human fertility is directly caused by exposure to the material. Long term exposure to high dust concentrations may cause changes in lung function i.e. pneumoconiosis; caused by particles less than 0.5 micron penetrating and remaining in the lung. Prime symptom is breathlessness; lung shadows show on X-ray.
- CAUTION: May produce immunosuppression in individuals occupationally exposed to the material.

Exposure to immunosuppressives may aggravate infectious diseases. Chronic exposure to therapeutic doses of compounds which produce immunosuppression has been associated with development of lymphomas (occasionally malignant) and mammary tumours. These may be secondary effects induced by activation of endogenous retroviruses.

Patients on immunosuppressive medications have a 10- to 100-fold increased risk of cancer compared to the general population. Furthermore, people who currently have or have already been treated for cancer have a higher rate of tumor progression and recurrence than patients with an intact immune system.

Patients receiving immunosuppressive regimens involving combinations of drugs, as part of an immunosuppressive regimen are at increased risk of developing lymphomas and other malignancies, particularly of the skin. The risk appears to be related to the intensity and duration of immunosuppression rather than to the use of any specific agent.

Increased incidences of neoplasms, in mice and humans, have been reported after long-term immunosuppression by azathioprine and cyclosporin. Cyclosporin has been classified as a human carcinogen, by IARC, based on development of lymphomas after repeated and prolonged exposures to therapeutic doses.

Treatment with cyclosporin A may be associated with the development of lymphomas with one study showing such development in 10% of transplant patients. Studies in mice revealed a trend towards the incidence of lymphomas at high doses. The increased incidence of lymphomas observed clinically in immunosuppressive patients may possibly be related to the degree of immunosuppression.

Section 3 - COMPOSITION / INFORMATION ON INGREDIENTS

HAZARD RATINGS

<table>
<thead>
<tr>
<th></th>
<th>Min</th>
<th>Max</th>
</tr>
</thead>
<tbody>
<tr>
<td>Flammability:</td>
<td>1</td>
<td></td>
</tr>
<tr>
<td>Toxicity:</td>
<td>2</td>
<td></td>
</tr>
<tr>
<td>Body Contact:</td>
<td>0</td>
<td></td>
</tr>
<tr>
<td>Reactivity:</td>
<td>1</td>
<td></td>
</tr>
<tr>
<td>Chronic:</td>
<td>3</td>
<td></td>
</tr>
</tbody>
</table>

NAME | CAS RN | %
--- | --- | ---
Section 4 - FIRST AID MEASURES

SWALLOWED

- IF SWALLOWED, REFER FOR MEDICAL ATTENTION, WHERE POSSIBLE, WITHOUT DELAY.
- Where Medical attention is not immediately available or where the patient is more than 15 minutes from a hospital or unless instructed otherwise:
  - For advice, contact a Poisons Information Center or a doctor.
  - Urgent hospital treatment is likely to be needed.
  - If conscious, give water to drink.
  - INDUCE vomiting with fingers down the back of the throat, ONLY IF CONSCIOUS. Lean patient forward or place on left side (head-down position, if possible) to maintain open airway and prevent aspiration.

NOTE: Wear a protective glove when inducing vomiting by mechanical means.

- In the mean time, qualified first-aid personnel should treat the patient following observation and employing supportive measures as indicated by the patient's condition.
- If the services of a medical officer or medical doctor are readily available, the patient should be placed in his/her care and a copy of the MSDS should be provided. Further action will be the responsibility of the medical specialist.
- If medical attention is not available on the worksite or surroundings send the patient to a hospital together with a copy of the MSDS.

EYE

- If this product comes in contact with the eyes:
  - Wash out immediately with fresh running water.
  - Ensure complete irrigation of the eye by keeping eyelids apart and away from eye and moving the eyelids by occasionally lifting the upper and lower lids.
  - If pain persists or recurs seek medical attention.
  - Removal of contact lenses after an eye injury should only be undertaken by skilled personnel.

SKIN

- If skin or hair contact occurs:
  - Flush skin and hair with running water (and soap if available).
  - Seek medical attention in event of irritation.

INHALED

- If fumes or combustion products are inhaled remove from contaminated area.
- Other measures are usually unnecessary.

NOTES TO PHYSICIAN

- for poisons (where specific treatment regime is absent):
  - BASIC TREATMENT
    - Establish a patent airway with suction where necessary.
    - Watch for signs of respiratory insufficiency and assist ventilation as necessary.
    - Administer oxygen by non-rebreather mask at 10 to 15 l/min.
    - Monitor and treat, where necessary, for pulmonary edema.
    - Monitor and treat, where necessary, for shock.
    - Anticipate seizures.
    - DO NOT use emetics. Where ingestion is suspected rinse mouth and give up to 200 ml water (5 ml/kg recommended) for dilution where patient is able to swallow, has a strong gag reflex and does not drool.
  - ADVANCED TREATMENT
    - Consider orotracheal or nasotracheal intubation for airway control in unconscious patient or where respiratory arrest has occurred.
    - Positive-pressure ventilation using a bag-valve mask might be of use.
    - Monitor and treat, where necessary, for arrhythmias.
    - Start an IV D5W TKO. If signs of hypovolemia are present use lactated Ringers solution. Fluid overload might create complications.
    - Drug therapy should be considered for pulmonary edema.
    - Hypotension with signs of hypovolemia requires the cautious administration of fluids. Fluid overload might create complications.
    - Treat seizures with diazepam.
    - Proparacaine hydrochloride should be used to assist eye irrigation.

BRONSTEIN, A.C. and CURRANCE, P.L.
EMERGENCY CARE FOR HAZARDOUS MATERIALS EXPOSURE: 2nd Ed. 1994.

Treat symptomatically.

Nephrotoxicity may be avoided by adequate hydration and mannitol diuresis. Absorption from the gastrointestinal tract is incomplete and variable. The absolute bioavailability of oral forms is 20-50% at steady state. Distributed largely outside blood volume and biotransformed to about 15 metabolites which all contain the intact cyclic peptide structure of the parent compound. Elimination is biphasic with an alpha half-life of about 2 hours and a beta (terminal) half-life of about 14 hours irrespective of the dose. Elimination is primarily biliary with only 6% secreted in the urine.

Section 5 - FIRE FIGHTING MEASURES

Vapour Pressure (mmHG): Negligible
Section 6 - ACCIDENTAL RELEASE MEASURES

MINOR SPILLS
- Clean up waste regularly and abnormal spills immediately.
- Avoid breathing dust and contact with skin and eyes.
- Wear protective clothing, gloves, safety glasses and dust respirator.
- Use dry clean up procedures and avoid generating dust.
- Vacuum up or sweep up. NOTE: Vacuum cleaner must be fitted with an exhaust micro filter (HEPA type) (consider explosion-proof machines designed to be grounded during storage and use).
- Dampen with water to prevent dusting before sweeping.
- Place in suitable containers for disposal.

MAJOR SPILLS
- Clear area of personnel and move upwind.
- Alert Emergency Responders and tell them location and nature of hazard.
- Wear full body protective clothing with breathing apparatus.
- Prevent, by all means available, spillage from entering drains or water courses.
- Consider evacuation (or protect in place).
- No smoking, naked lights or ignition sources.
- Increase ventilation.
- Stop leak if safe to do so.
- Water spray or fog may be used to disperse / absorb vapour.
- Contain or absorb spill with sand, earth or vermiculite.
- Collect recoverable product into labelled containers for recycling.
- Collect solid residues and seal in labelled drums for disposal.
- Wash area and prevent runoff into drains.
- After clean up operations, decontaminate and launder all protective clothing and equipment before storing and re-using.
- If contamination of drains or waterways occurs, advise emergency services.

ACUTE EXPOSURE GUIDELINE LEVELS (AEGL) (in ppm)
AEGL 1: The airborne concentration of a substance above which it is predicted that the general population, including susceptible individuals, could experience notable discomfort, irritation, or certain asymptomatic nonsensory effects. However, the effects are not disabling and are transient and reversible upon cessation of exposure.

AEGL 2: The airborne concentration of a substance above which it is predicted that the general population, including susceptible individuals, could experience irreversible or other serious, long-lasting adverse health effects or an impaired ability to escape.

AEGL 3: The airborne concentration of a substance above which it is predicted that the general population, including susceptible individuals, could experience life-threatening health effects or death.

**Section 7 - HANDLING AND STORAGE**

**PROCEDURE FOR HANDLING**

- Avoid all personal contact, including inhalation.
- Wear protective clothing when risk of exposure occurs.
- Use in a well-ventilated area.
- Prevent concentration in hollows and sumps.
- DO NOT enter confined spaces until atmosphere has been checked.
- DO NOT allow material to contact humans, exposed food or food utensils.
- Avoid contact with incompatible materials.
- When handling, DO NOT eat, drink or smoke.
- Keep containers securely sealed when not in use.
- Avoid physical damage to containers.
- Always wash hands with soap and water after handling.
- Work clothes should be laundered separately.
- Launder contaminated clothing before re-use.
- Use good occupational work practice.
- Observe manufacturer's storing and handling recommendations.
- Atmosphere should be regularly checked against established exposure standards to ensure safe working conditions are maintained.

Empty containers may contain residual dust which has the potential to accumulate following settling. Such dusts may explode in the presence of an appropriate ignition source.
- Do NOT cut, drill, grind or weld such containers
- In addition ensure such activity is not performed near full, partially empty or empty containers without appropriate workplace safety authorisation or permit.

**RECOMMENDED STORAGE METHODS**

- Glass container.
- Polyethylene or polypropylene container.
- Check all containers are clearly labelled and free from leaks.

**STORAGE REQUIREMENTS**

- Store in original containers.
- Keep containers securely sealed.
- Store in a cool, dry, well-ventilated area.
- Store away from incompatible materials and foodstuff containers.
- Protect containers against physical damage and check regularly for leaks.
- Observe manufacturer's storing and handling recommendations.

**SAFE STORAGE WITH OTHER CLASSIFIED CHEMICALS**

- Glass container.
- Polyethylene or polypropylene container.
- Check all containers are clearly labelled and free from leaks.

**Section 8 - EXPOSURE CONTROLS / PERSONAL PROTECTION**

**EXPOSURE CONTROLS**

The following materials had no OELs on our records
- cyclosporin A: CAS:59865-13-3

**MATERIAL DATA**

**CYCLOSPORIN A:**

- It is the goal of the ACGIH (and other Agencies) to recommend TLVs (or their equivalent) for all substances for which there is evidence of health effects at airborne concentrations encountered in the workplace.
At this time no TLV has been established, even though this material may produce adverse health effects (as evidenced in animal experiments or clinical experience). Airborne concentrations must be maintained as low as is practically possible and occupational exposure must be kept to a minimum. 

NOTE: The ACGIH occupational exposure standard for Particles Not Otherwise Specified (P.N.O.S) does NOT apply. Airborne particulate or vapor must be kept to levels as low as is practicably achievable given access to modern engineering controls and monitoring hardware. Biologically active compounds may produce idiosyncratic effects which are entirely unpredictable on the basis of literature searches and prior clinical experience (both recent and past).

PERSONAL PROTECTION

Consult your EHS staff for recommendations

EYE
- When handling very small quantities of the material eye protection may not be required.
For laboratory, larger scale or bulk handling or where regular exposure in an occupational setting occurs:
  - Chemical goggles
  - Face shield. Full face shield may be required for supplementary but never for primary protection of eyes
  - Contact lenses may pose a special hazard; soft contact lenses may absorb and concentrate irritants. A written policy document, describing the wearing of lenses or restrictions on use, should be created for each workplace or task. This should include a review of lens absorption and adsorption for the class of chemicals in use and an account of injury experience. Medical and first-aid personnel should be trained in their removal and suitable equipment should be readily available. In the event of chemical exposure, begin eye irrigation immediately and remove contact lens as soon as practicable. Lens should be removed at the first signs of eye redness or irritation - lens should be removed in a clean environment only after workers have washed hands thoroughly. [CDC NIOSH Current Intelligence Bulletin 59]

HANDS/FEET
- Suitability and durability of glove type is dependent on usage. Important factors in the selection of gloves include: such as:
  - frequency and duration of contact,
  - chemical resistance of glove material,
  - glove thickness and
dexterity
Select gloves tested to a relevant standard (e.g. Europe EN 374, US F739).
- When prolonged or frequently repeated contact may occur, a glove with a protection class of 5 or higher (breakthrough time greater than 240 minutes according to EN 374) is recommended.
- When only brief contact is expected, a glove with a protection class of 3 or higher (breakthrough time greater than 60 minutes according to EN 374) is recommended.
- Contaminated gloves should be replaced.
Gloves must only be worn on clean hands. After using gloves, hands should be washed and dried thoroughly. Application of a non-perfumed moisturiser is recommended.
  - Rubber gloves (nitrile or low-protein, powder-free latex). Employees allergic to latex gloves should use nitrile gloves in preference.
  - Double gloving should be considered.
  - PVC gloves.
  - Protective shoe covers.
  - Head covering.
Experience indicates that the following polymers are suitable as glove materials for protection against undissolved, dry solids, where abrasive particles are not present.
  - polychloroprene
  - nitrile rubber
  - butyl rubber
  - fluoroplastic
  - polyvinyl chloride
Gloves should be examined for wear and/ or degradation constantly.

OTHER
- Employees working with confirmed human carcinogens should be provided with, and be required to wear, clean, full body protective clothing (smocks, coveralls, or long-sleeved shirt and pants), shoe covers and gloves prior to entering the regulated area.
- Employees engaged in handling operations involving carcinogens should be provided with, and required to wear and use half-face filter-type respirators with filters for dusts, mists and fumes, or air purifying canisters or cartridges. A respirator affording higher levels of protection may be substituted.
- Emergency deluge showers and eyewash fountains, supplied with potable water, should be located near, within sight of, and on the same level with locations where direct exposure is likely.
- Prior to each exit from an area containing confirmed human carcinogens, employees should be required to remove and leave protective clothing and equipment at the point of exit and at the last exit of the day, to place used clothing and equipment in impervious containers at the point of exit for purposes of decontamination or disposal. The contents of such impervious containers must be identified with suitable labels. For maintenance and decontamination activities, authorized employees entering the area should be provided with and required to wear clean, impervious garments, including gloves, boots and continuous-air supplied hood.
- Prior to removing protective garments the employee should undergo decontamination and be required to shower upon removal of the garments and hood.
- For quantities up to 500 grams a laboratory coat may be suitable.
- For quantities up to 1 kilogram a disposable laboratory coat or coverall of low permeability is recommended. Coveralls should be buttoned at collar and cuffs.
- For quantities over 1 kilogram and manufacturing operations, wear disposable coverall of low permeability and disposable
For manufacturing operations, air-supplied full body suits may be required for the provision of advanced respiratory protection.

Eye wash unit.

Ensure there is ready access to an emergency shower.

For Emergencies: Vinyl suit

Respirators may be necessary when engineering and administrative controls do not adequately prevent exposures.

The decision to use respiratory protection should be based on professional judgment that takes into account toxicity information, exposure measurement data, and frequency and likelihood of the worker's exposure - ensure users are not subject to high thermal loads which may result in heat stress or distress due to personal protective equipment (powered, positive flow, full face apparatus may be an option).

Published occupational exposure limits, where they exist, will assist in determining the adequacy of the selected respiratory protection. These may be government mandated or vendor recommended.

Certified respirators will be useful for protecting workers from inhalation of particulates when properly selected and fit tested as part of a complete respiratory protection program.

Try to avoid creating dust conditions.

<table>
<thead>
<tr>
<th>Protection Factor</th>
<th>Half-Face Respirator</th>
<th>Full-Face Respirator</th>
<th>Powered Air Respirator</th>
</tr>
</thead>
<tbody>
<tr>
<td>10 x PEL</td>
<td>Air-line*</td>
<td>P1</td>
<td>PAPR-P1</td>
</tr>
<tr>
<td>50 x PEL</td>
<td>Air-line**</td>
<td>P2</td>
<td>PAPR-P2</td>
</tr>
<tr>
<td>100 x PEL</td>
<td>-</td>
<td>P3</td>
<td>-</td>
</tr>
<tr>
<td>100+ x PEL</td>
<td>Air-line**</td>
<td>-</td>
<td>Air-line** PAPR-P3</td>
</tr>
</tbody>
</table>

* - Negative pressure demand ** - Continuous flow

Examination of Respirator Codes:
Class 1 low to medium absorption capacity filters.
Class 2 medium absorption capacity filters.
Class 3 high absorption capacity filters.
PAPR Powered Air Purifying Respirator (positive pressure) cartridge.

Type A for use against certain organic gases and vapors.
Type AX for use against low boiling point organic compounds (less than 65°C).
Type B for use against certain inorganic gases and other acid gases and vapors.
Type E for use against sulfur dioxide and other acid gases and vapors.
Type K for use against ammonia and organic ammonia derivatives

Class P1 intended for use against mechanically generated particulates of sizes most commonly encountered in industry, e.g. asbestos, silica.
Class P2 intended for use against both mechanically and thermally generated particulates, e.g. metal fume.
Class P3 intended for use against all particulates containing highly toxic materials, e.g. beryllium.

The local concentration of material, quantity and conditions of use determine the type of personal protective equipment required.

Use appropriate NIOSH-certified respirator based on informed professional judgement. In conditions where no reasonable estimate of exposure can be made, assume the exposure is in a concentration IDLH and use NIOSH-certified full face pressure demand SCBA with a minimum service life of 30 minutes, or a combination full facepiece pressure demand SAR with auxiliary self-contained air supply. Respirators provided only for escape from IDLH atmospheres shall be NIOSH-certified for escape from the atmosphere in which they will be used.

ENGINEERING CONTROLS

Employees exposed to confirmed human carcinogens should be authorized to do so by the employer, and work in a regulated area.

Work should be undertaken in an isolated system such as a “glove-box”. Employees should wash their hands and arms upon completion of the assigned task and before engaging in other activities not associated with the isolated system.

Within regulated areas, the carcinogen should be stored in sealed containers, or enclosed in a closed system, including piping systems, with any sample ports or openings closed while the carcinogens are contained within.

Open-vessel systems are prohibited.

Each operation should be provided with continuous local exhaust ventilation so that air movement is always from ordinary work areas to the operation.

Exhaust air should not be discharged to regulated areas, non-regulated areas or the external environment unless decontaminated. Clean make-up air should be introduced in sufficient volume to maintain correct operation of the local exhaust system.

For maintenance and decontamination activities, authorized employees entering the area should be provided with and required to wear clean, impervious garments, including gloves, boots and continuous-air supplied hood. Prior to removing protective garments the employee should undergo decontamination and be required to shower upon removal of the garments and hood.

Except for outdoor systems, regulated areas should be maintained under negative pressure (with respect to non-regulated areas).

Local exhaust ventilation requires make-up air be supplied in equal volumes to replaced air.

Laboratory hoods must be designed and maintained so as to draw air inward at an average linear face velocity of 150 feet/ min. with a minimum of 125 feet/ min. Design and construction of the fume hood requires that insertion of any portion of the employees body, other than hands and arms, be disallowed.

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

PHYSICAL PROPERTIES

Solid.

Does not mix with water.
<table>
<thead>
<tr>
<th>Property</th>
<th>Value</th>
<th>Property</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>State</td>
<td>Divided solid</td>
<td>Molecular Weight</td>
<td>1202.62</td>
</tr>
<tr>
<td>Melting Range (°F)</td>
<td>298.4 - 303.8</td>
<td>Viscosity</td>
<td>Not Applicable</td>
</tr>
<tr>
<td>Boiling Range (°F)</td>
<td>Not available</td>
<td>Solubility in water (g/L)</td>
<td>Partly miscible</td>
</tr>
<tr>
<td>Flash Point (°F)</td>
<td>Not available</td>
<td>pH (1% solution)</td>
<td>Not applicable</td>
</tr>
<tr>
<td>Decomposition Temp (°F)</td>
<td>Not available</td>
<td>pH (as supplied)</td>
<td>Not applicable</td>
</tr>
<tr>
<td>Autoignition Temp (°F)</td>
<td>Not available</td>
<td>Vapour Pressure (mmHg)</td>
<td>Negligible</td>
</tr>
<tr>
<td>Upper Explosive Limit (%)</td>
<td>Not available</td>
<td>Specific Gravity (water=1)</td>
<td>Not available</td>
</tr>
<tr>
<td>Lower Explosive Limit (%)</td>
<td>Not available</td>
<td>Relative Vapor Density (air=1)</td>
<td>Not Applicable</td>
</tr>
<tr>
<td>Volatile Component (%vol)</td>
<td>Negligible</td>
<td>Evaporation Rate</td>
<td>Not applicable</td>
</tr>
</tbody>
</table>

**APPEARANCE**

White crystalline powder; does not mix well with water. Soluble in methanol, ethanol, acetone, ether, chloroform.

### Section 10 - CHEMICAL STABILITY

#### CONDITIONS CONTRIBUTING TO INSTABILITY
- Presence of incompatible materials.
- Product is considered stable.
- Hazardous polymerization will not occur.

#### STORAGE INCOMPATIBILITY
- Avoid reaction with oxidizing agents.

For incompatible materials - refer to Section 7 - Handling and Storage.

### Section 11 - TOXICOLOGICAL INFORMATION

**cyclosporin A**

#### TOXICITY AND IRRITATION
- unless otherwise specified data extracted from RTECS - Register of Toxic Effects of Chemical Substances.

<table>
<thead>
<tr>
<th>Route</th>
<th>Value</th>
<th>Route</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Oral (rat) LD50</td>
<td>1480 mg/kg</td>
<td>Intraperitoneal (rat) LD50</td>
<td>147 mg/kg</td>
</tr>
<tr>
<td>Subcutaneous (rat) LD50</td>
<td>286 mg/kg</td>
<td>Intravenous (rat) LD50</td>
<td>24 mg/kg</td>
</tr>
<tr>
<td>Oral (mouse) LD50</td>
<td>2329 mg/kg</td>
<td>Intravenous (mouse) LD50</td>
<td>96 mg/kg</td>
</tr>
<tr>
<td>Oral (rabbit) LD50</td>
<td>&gt;1000 mg/kg</td>
<td>Intravenous (rabbit) LD50</td>
<td>10 mg/kg</td>
</tr>
</tbody>
</table>

Spasticity, headache, acute arterial occlusion, cyanosis, diarrhoea, changes in kidney tubules, lymphoma, paternal effects, maternal effects, effects on fertility, foetolethality, specific developmental abnormalities (craniofacial) recorded.

#### CARCINOGEN

<table>
<thead>
<tr>
<th>Substance</th>
<th>Reference(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>cyclosporin A</td>
<td>NTP-C</td>
</tr>
</tbody>
</table>

### Section 12 - ECOLOGICAL INFORMATION

**Ecotoxicity**

<table>
<thead>
<tr>
<th>Ingredient</th>
<th>Persistence: Water/Soil</th>
<th>Persistence: Air</th>
<th>Bioaccumulation</th>
<th>Mobility</th>
</tr>
</thead>
<tbody>
<tr>
<td>cyclosporin A</td>
<td>HIGH</td>
<td></td>
<td>LOW</td>
<td>LOW</td>
</tr>
</tbody>
</table>

### Section 13 - DISPOSAL CONSIDERATIONS

#### Disposal Instructions

- All waste must be handled in accordance with local, state and federal regulations.
- Puncture containers to prevent re-use and bury at an authorized landfill.
- Legislation addressing waste disposal requirements may differ by country, state and/ or territory. Each user must refer to laws operating in their area. In some areas, certain wastes must be tracked.
- A Hierarchy of Controls seems to be common - the user should investigate:
  - Reduction
  - Reuse
  - Recycling
Disposal (if all else fails)
This material may be recycled if unused, or if it has not been contaminated so as to make it unsuitable for its intended use. Shelf life considerations should also be applied in making decisions of this type. Note that properties of a material may change in use, and recycling or reuse may not always be appropriate.

- DO NOT allow wash water from cleaning equipment to enter drains. Collect all wash water for treatment before disposal.
- Recycle wherever possible.
- Consult manufacturer for recycling options or consult Waste Management Authority for disposal if no suitable treatment or disposal facility can be identified.
- Dispose of by: Burial in a licensed land-fill or Incineration in a licensed apparatus (after admixture with suitable combustible material)
- Decontaminate empty containers. Observe all label safeguards until containers are cleaned and destroyed.

Section 14 - TRANSPORTATION INFORMATION

NOT REGULATED FOR TRANSPORT OF DANGEROUS GOODS: DOT, IATA, IMDG

Section 15 - REGULATORY INFORMATION

cyclosporin A (CAS: 59865-13-3) is found on the following regulatory lists;

Section 16 - OTHER INFORMATION

LIMITED EVIDENCE

- Possible cancer-causing agent*.
- * (limited evidence).

Reasonable care has been taken in the preparation of this information, but the author makes no warranty of merchantability or any other warranty, expressed or implied, with respect to this information. The author makes no representations and assumes no liability for any direct, incidental or consequential damages resulting from its use. For additional technical information please call our toxicology department on +800 CHEMCALL.

Classification of the mixture and its individual components has drawn on official and authoritative sources as well as independent review by the Chemwatch Classification committee using available literature references. A list of reference resources used to assist the committee may be found at: www.chemwatch.net/references.

The (M)SDS is a Hazard Communication tool and should be used to assist in the Risk Assessment. Many factors determine whether the reported Hazards are Risks in the workplace or other settings. Risks may be determined by reference to Exposures Scenarios. Scale of use, frequency of use and current or available engineering controls must be considered.

This document is copyright. Apart from any fair dealing for the purposes of private study, research, review or criticism, as permitted under the Copyright Act, no part may be reproduced by any process without written permission from CHEMWATCH. TEL (+61 3) 9572 4700.

Issue Date: Oct-28-2009
Print Date: Apr-21-2010